The recent availability of different p‐tau biomarkers such as p‐tau217 and p‐tau231 capable of detecting very early AD pathological processes (Suarez‐Calvet et al, 2020) has highlighted the additional need for a staging biomarker for the long asymptomatic phase of the disease. This evidence concerns the gene MAPT and Alzheimer disease.